PMID- 15965645
OWN - NLM
STAT- MEDLINE
DCOM- 20050929
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 54
IP  - 10
DP  - 2005 Oct
TI  - Dendritic cells pulsed with gp96-peptide complexes derived from human 
      hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.
PG  - 971-80
AB  - Dendritic cells (DCs) are one of the most potent antigen-presenting cells (APCs) 
      capable of activating immune responses. Different forms of tumor antigens have 
      been used to load DCs to initiate tumor-specific immune responses. Heat shock 
      proteins (HSPs) are considered natural adjuvants which have the ability to 
      chaperone peptides associated with them presented efficiently by interaction with 
      professional APCs through specific receptors. In the present study, we used HSP, 
      gp96-peptide complexes, derived from human hepatocellular carcinoma (HCC) cells 
      as antigens for pulsing DCs. We found that gp96-peptide complexes derived from 
      HCC cells induced the maturation of DCs by enhancing expression of human 
      leukocyte antigen class II, CD80, CD86, CD40, and CD83. The matured DCs 
      stimulated a high level of autologous T cell proliferation and induced HCC 
      specific cytotoxic T lymphocytes, which specifically killed HCC cells by a major 
      histocompatability complex (MHC) class I restricted mechanism. These findings 
      demonstrate that DCs pulsed with gp96-peptide complexes derived from HCC cells 
      are effective in activating specific T cell responses against HCC cells.
FAU - Wang, X H
AU  - Wang XH
AD  - Department of Biology, The Hong Kong University of Science and Technology, Clear 
      Water Bay, Kowloon, Hong Kong SAR, P. R. China.
FAU - Qin, Y
AU  - Qin Y
FAU - Hu, M H
AU  - Hu MH
FAU - Xie, Y
AU  - Xie Y
LA  - eng
PT  - Journal Article
DEP - 20050618
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (CD86 protein, human)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (sarcoma glycoprotein gp96 rejection antigens)
SB  - IM
MH  - Antigen Presentation/immunology
MH  - Antigens, CD/immunology/metabolism
MH  - Antigens, Neoplasm/*immunology
MH  - B7-2 Antigen
MH  - CD40 Antigens/immunology/metabolism
MH  - Carcinoma, Hepatocellular/*immunology
MH  - Cell Proliferation
MH  - Dendritic Cells/*immunology
MH  - Heat-Shock Proteins/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunoglobulins/immunology/metabolism
MH  - Liver Neoplasms/immunology
MH  - Lymphocyte Activation/*immunology
MH  - Membrane Glycoproteins/immunology/metabolism
MH  - Peptide Fragments/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - CD83 Antigen
PMC - PMC11032807
EDAT- 2005/06/21 09:00
MHDA- 2005/09/30 09:00
PMCR- 2005/06/18
CRDT- 2005/06/21 09:00
PHST- 2004/07/20 00:00 [received]
PHST- 2004/12/09 00:00 [accepted]
PHST- 2005/06/21 09:00 [pubmed]
PHST- 2005/09/30 09:00 [medline]
PHST- 2005/06/21 09:00 [entrez]
PHST- 2005/06/18 00:00 [pmc-release]
AID - 662 [pii]
AID - 10.1007/s00262-005-0662-9 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2005 Oct;54(10):971-80. doi: 
      10.1007/s00262-005-0662-9. Epub 2005 Jun 18.